2. Analisis probabilistik Bidang efektivitas biaya. Setiap titik adalah satu simulasi probabilistik. Titik di bawah sumbu nol berarti intervensi menurunkan biaya.-10 0 10 20 30 -0,80 -0,60 -0,40 -0,20 -0,00 0,20 0,40 Tambahan tahun hidup berkualitas per pasien (QALY) Tambahan biaya per pasien (juta rupiah) 1 kali PDB per kapita 3 kali PDB per kapita Simulasi probabilistik (500 sampel) Kasus dasarKurva penerimaan. Peluang intervensi hemat biaya pada berbagai ambang kesediaan membayar.0 20 40 60 80 100 0 50 100 150 200 250 Ambang kesediaan membayar (juta rupiah per QALY) Peluang hemat biaya (%) 75 juta 225 juta 13,3% 3. Analisis sensitivitas Analisis sensitivitas satu arah. Sepuluh parameter dengan pengaruh terbesar terhadap manfaat moneter bersih.-20 -10 0 10 20 30 interventions pioglitazone 15 30mg plus metformin transition rate multipliers uncontrolled t2dm to major diabetes complication interventions pioglitazone 15 30mg...interventions gliclazide MR plus metformin transition rate multipliers uncontrolled t2dm to major diabetes complication interventions gliclazide MR plus m...interventions pioglitazone 15 30mg plus metformin transition rate multipliers controlled t2dm to major diabetes complication interventions pioglitazone 15 30mg...interventions gliclazide MR plus metformin transition rate multipliers controlled t2dm to major diabetes complication interventions gliclazide MR plus m...interventions pioglitazone 15 30mg plus metformin transition rate multipliers uncontrolled t2dm to controlled t2dm interventions pioglitazone 15 30mg...interventions gliclazide MR plus metformin transition rate multipliers uncontrolled t2dm to controlled t2dm interventions gliclazide MR plus m...annual care costs idr major diabetes complication annual care costs idr major diabet...utility values major diabetes complication utility values major diabetes comp...transition rates annual controlled t2dm to major diabetes complication transition rates annual controlled...interventions pioglitazone 15 30mg plus metformin annual drug cost idr interventions pioglitazone 15 30mg...Perubahan manfaat moneter bersih per pasien (juta rupiah) Parameter Parameter pada nilai rendah Parameter pada nilai tinggi5. Validasi model Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0000%).
6. Penyesuaian untuk Indonesia Uraian berikut tersedia dalam bahasa Inggris.
KMK 1199/2025 Fornas status was re-audited for this indication and formulation through the official decision page: https://farmalkes.kemkes.go.id/unduh/keputusan-menteri-kesehatan-republik-indonesia-nomor-hk-01-07-menkes-1199-2025-tentang-formularium-nasional/ The searchable e-Fornas catalogue was cross-checked at: https://e-fornas.farmalkes.kemkes.go.id/guest/landing Policy route: Existing conditional FKTP optimization. Does low-cost pioglitazone add sufficient glycaemic value to offset heart-failure, oedema and fracture risk? PROactive informs cardiovascular benefit and heart-failure harm: https://pubmed.ncbi.nlm.nih.gov/16214598/ WHO diabetes medicine guideline: https://www.who.int/publications/i/item/9789241550284